Phase 3Completed
Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin
A Multicenter, Randomized, Double-Blind, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Insulin Alone or on Insulin in Combination With Metformin
- Sponsor
- AstraZeneca (Industry)
- Enrollment
- 455 enrolled
- Conditions
- Type 2 Diabetes
- Interventions
- Saxagliptin, 5 mg + insulin; Placebo + insulin
- Ages
- adults, older adults
- Registry
- NCT00757588
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to compare the effects of saxagliptin with those of placebo as add-on therapy to insulin and insulin with metformin in improving glycemic control at 24 and 52 weeks.
Primary outcomes
- Adjusted Mean Change From Baseline in A1C Levels (Last Observation Carried Forward [LOCF])
History
Last registry update
Results first posted
Primary completion
Started
Registered